Novartis' Cosentyx Gives More Additional Benefit Than Stelara, Says German HTA
This article was originally published in Scrip
Executive Summary
Novartis AG's Cosentyx (secukinumab) offers some plaque psoriasis patients "considerable additional benefit" over Johnson & Johnson's Stelara (ustekinumab), says the G-BA, the body in charge of Germany's AMNOG benefit assessment and pricing process. The news means that Novartis should find it easier to argue a better price during negotiations with health insurers.